Stock Price Quote

BAL PHARMA LTD.

NSE : BALPHARMABSE : 524824ISIN CODE : INE083D01012Industry : Pharmaceuticals & DrugsHouse : Private
BSE107.471.12 (+1.05 %)
PREV CLOSE ( ) 106.35
OPEN PRICE ( ) 106.42
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 21751
TODAY'S LOW / HIGH ( )104.80 114.84
52 WK LOW / HIGH ( )59.69 124.68
NSE107.421.21 (+1.14 %)
PREV CLOSE( ) 106.21
OPEN PRICE ( ) 105.60
BID PRICE (QTY) 107.42 (158)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 316936
TODAY'S LOW / HIGH( ) 104.13 114.95
52 WK LOW / HIGH ( )60 124.6
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987
Management Info
Shailesh Siroya - Chairman Shailesh Siroya - Managing Director
Registered Office

Address #21&22, Bommasandra Industrial Area,Anekal Taluk, ,
Bengaluru,
Karnataka-560099

Phone 080 41570811 / 13 / 19

Email investor@balpharma.com

Website www.balpharma.com

Registrars Details
MUFG Intime India Pvt Ltd.
C-101, 1st Floor,247 Park, Lal Bahadur Shastri Marg,Vikhroli West,Mumbai
 Listing : BSE, NSE

NEWS

10Sep Clarification Regarding Movement In P
Clarification regarding Movement in Price asper attachment
27Aug Bal Pharma submits intimation of recor
Bal Pharma has informed that the Company has fixed 17th September 2026 a..
26Aug Bal Pharma informs about AGM
Bal Pharma has informed that 39th AGM of Bal Pharma Limited Scheduled to..
25Aug Bal Pharma informs about updates
Bal Pharma has informed that in continuation of the Company's earlier in..
25Aug Clarification With Respect To Tentati
This is in Continuation of Company earlier intimation made in connection..
MORE

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit11.609999999999967.5200000000004
Gross Profit 11.6099999999999 63.6600000000004
Operating Profit 84.0899999999999342.35
Net Sales 884.273107.97
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  25586.10 (1.24%)
M.Cap ( in Cr)54368.68
Kwality Pharma (BSE)
peergroup  3642.50 (3.65%)
M.Cap ( in Cr)3779.53
Concord Biotech (BSE)
peergroup  1506.65 (3.72%)
M.Cap ( in Cr)15762.00
Rubicon Research (BSE)
peergroup  1838.35 (2.67%)
M.Cap ( in Cr)30430.56
Onesource Specialty (BSE)
peergroup  1592.40 (3.04%)
M.Cap ( in Cr)18260.51
MORE

Shareholding Pattern

PROMOTERS 50.86%
NON-INSTITUTION 48.99%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%
MORE

About Bal Pharma Ltd.

Bal Pharma Ltd. was incorporated in the year 1987. Its today's share price is 107.47. Its current market capitalisation stands at Rs 171.1 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3107.97 Cr and Total Income of Rs.3128 Cr. The company's management includes Bheekamchand Mukesh, Nicola Neeladri, Jatish Sheth, Ravindra Kumar Kothari, Shailesh Siroya, Shailesh Siroya, Shreepada ML.

It is listed on the BSE with a BSE Code of 524824 , NSE with an NSE Symbol of BALPHARMA and ISIN of INE083D01012. It's Registered office is at #21&22, Bommasandra Industrial Area,Anekal Taluk, Bengaluru-560099, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are NSVM & Associates, SSJNB & Co, TD Jain & DI Sakaria, TD Jain & Dl Sakria

download beyond app
download beyond app

About Nirmal Bang

About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support

Product & Services

Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Algo Trading

Equity

Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities

Derivatives

Updates Market Report Overview

IPO

IPO Issues Performance News & Analysis

Commodities

Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges

Portfolio Management Service (PMS)

PMS Disclosure Document Nirmal Bang PMS - Investor Charter NB PMS Insights SCORES complaints – August 2026 Online Grievance Portal – SCORES Online Dispute Resolution Portal – ODR Fee Calculator UPI ID - QR Code & Forms Empaneled Distributors Contact Us

Mutual Funds

About Nirmal Bang Wealth Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy

NPS

NPS Forms and Guidelines NPS-AML Policy NPS - Operational Guidelines

Nirmal Bang Research

Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data Important Update IRRA

Other Links

Disclaimer Privacy Policy Policies and Procedures Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SCORES and ‘SMARTODR portal
RMS Policy
RMS Policy Auto Square Off Policy
Inspection SORM Policy - NBEPL CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023 FY-2023-2024 FY-2024-2025 FY-2025-2026 FY-2026-2027
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker RA NBEPL Investor Charter RA NBSPL Investor Charter Investor Complaints -RA Investor Complaints-NBEPL Investor NBCPL Investor NBEPL RA Investor NBSPL-RA
Evoting
NSDL Evoting CDSL Evoting
Compliance Annual report
NBSPL ACR Report Signed Annexure – NBSPL NBEPL ACR Report Signed Annexure – NBEPL
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’s Surrendered List of AP’s KYC Activation Process Voluntary Freezing Blocking of Online Trading Account Internal Shortage Policy MCXCCL Client Reports Policy For GTC/GTD RBI Guidelines Transfer of Funds via SEBI-Validated UPI ID MTF Terms Master Circular for Online Dispute Resolution
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatment NBSPL Policy of AML NBEPL Policy of AML NBSPL Policy of Surveillance NBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For Any Legal Department Grievances – Level 1, Please Get In Touch With Mr. Bhavin Pandya On 022-6273 9232 Or Write A Mail To bhavin.pandya@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Legal Department Grievances – Level 2, Please Get In Touch With Mr. Kishor Kumar Agrawal On 022-6273 9252/9253 Or Write A Mail To kishorkumar.agrawal@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Compliance Grievances / other grievances , Please Get In Touch With Mr. Samir Kamdar On 022-62739395/9396 Or Write A Mail To samir.kamdar@nirmalbang.com With Subject line As Grievances/Complaint.     |    
IMPORTANT LINKS: SEBI BSE NSE MCX CDSL NSDL NCDEX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.